+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lipid-lowering therapy with pravastatin reduces coronary plaque volume Role of high-density lipoprotein cholesterol containing apolipoprotein A-1



Lipid-lowering therapy with pravastatin reduces coronary plaque volume Role of high-density lipoprotein cholesterol containing apolipoprotein A-1



Journal of the American College of Cardiology 41(6 Suppl. A): 296A




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 035225838

Download citation: RISBibTeXText

DOI: 10.1016/s0735-1097(03)82386-0


Related references

Pravastatin reduces major coronary events in patients with low levels of both high-density lipoprotein cholesterol and low-density lipoprotein cholesterol Results from the LIPID Study. Journal of the American College of Cardiology 37(2 Suppl. A): 262A, 2001

Role of the Low-Density Lipoprotein-Cholesterol/High-Density Lipoprotein-Cholesterol Ratio in Predicting Serial Changes in the Lipid Component of Coronary Plaque. Circulation Journal 81(10): 1439-1446, 2017

Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. Journal Of The American College Of Cardiology. 23(4): 899-906, 1994

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. European Heart Journal 25(9): 771-777, 2004

Low-density lipoprotein-cholesterol/high-density lipoprotein-cholesterol ratio predicts lipid-rich coronary plaque in patients with coronary artery disease--integrated-backscatter intravascular ultrasound study. Circulation Journal 74(7): 1392-1398, 2010

Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization. American Journal of Cardiology 86(12A): 28L-34L, 2000

Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization. American Journal of Cardiology 86(12a): 28l-34l, 2001

Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 112(22): 3368-3370, 2005

Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106(20): 2526-2529, 2002

Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 107(20): E199, 2003

Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. Journal of the American College of Cardiology 52(11): 914-920, 2008

Combined use of apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol before routine clinical lipid measurement in predicting coronary heart disease. Coronary Artery Disease 25(5): 433-438, 2015

Reduction of coronary events by pravastatin--is lowering low-density lipoprotein cholesterol the answer?. American Journal of Cardiology 80(5): 683, 1997

Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. Journal of the American College of Cardiology 52(8): 626-632, 2008

Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography. Heart and Vessels 33(4): 351-357, 2017